276 related articles for article (PubMed ID: 26296968)
1. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M
Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968
[TBL] [Abstract][Full Text] [Related]
2. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
5. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes.
Meng F; Yamagiwa Y; Ueno Y; Patel T
J Hepatol; 2006 Jun; 44(6):1055-65. PubMed ID: 16469407
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.
Kobayashi S; Werneburg NW; Bronk SF; Kaufmann SH; Gores GJ
Gastroenterology; 2005 Jun; 128(7):2054-65. PubMed ID: 15940637
[TBL] [Abstract][Full Text] [Related]
8. Stathmin decreases cholangiocarcinoma cell line sensitivity to staurosporine-triggered apoptosis via the induction of ERK and Akt signaling.
Wang Y; Gao Z; Zhang D; Bo X; Wang Y; Wang J; Shen S; Liu H; Suo T; Pan H; Ai Z; Liu H
Oncotarget; 2017 Feb; 8(9):15775-15788. PubMed ID: 28178656
[TBL] [Abstract][Full Text] [Related]
9. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
Bian SB; Yang Y; Liang WQ; Zhang KC; Chen L; Zhang ZT
Ann N Y Acad Sci; 2021 Jan; 1484(1):74-89. PubMed ID: 32827446
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ
Hepatology; 2005 Dec; 42(6):1329-38. PubMed ID: 16317687
[TBL] [Abstract][Full Text] [Related]
14. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma.
Zhao X; Wen F; Wang W; Lu Z; Guo Q
Nutr Cancer; 2019; 71(2):246-256. PubMed ID: 30633583
[TBL] [Abstract][Full Text] [Related]
15. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
16. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.
Isomoto H; Mott JL; Kobayashi S; Werneburg NW; Bronk SF; Haan S; Gores GJ
Gastroenterology; 2007 Jan; 132(1):384-96. PubMed ID: 17241887
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
19. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
20. Leukemia inhibitory factor regulates marmoset induced pluripotent stem cell proliferation via a PI3K/Akt‑dependent Tbx‑3 activation pathway.
Ke M; He Q; Hong D; Li O; Zhu M; Ou WB; He Y; Wu Y
Int J Mol Med; 2018 Jul; 42(1):131-140. PubMed ID: 29620145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
